WebI am a nanomedicine scientist with academic and industry experience in the field of lipid-based drug delivery systems for small molecule therapeutics, proteins, and genetic drugs. As a researcher, I have made major contributions in the design and development of lipid nanoparticles (LNP). Most notably, my work has described the biophysical processes of … WebNucleic acid reagents, including plasmid-encoded genes and small interfering RNA (siRNA), are promising tools for validating gene function and for the development of therapeutic agents. Native β-cyclodextrins (BCDs) have limited efficiency in gene delivery due to their instable complexes with nucleic acid. We hypothesized that cationic BCD nanoparticles …
Pharmaceutics Free Full-Text Tetraethylenepentamine-Coated …
WebMar 18, 2024 · Design and Development of RNA-Based Therapeutics for Systemic Delivery Despite the promising potential of RNA-based therapeutics, delivery strategies are required for the successful translation of ASOs and siRNA into the clinic. There are two broad strategies to improve the systemic delivery of RNA-based therapeutics. Webthe design of siRNA therapeutics in three broad categories: i.) selection of a disease and target mRNA, ii.) design of a highly-active siRNA, and iii.) design of the siRNA delivery … profitable hobbies for men
Delivery of siRNA to the Eye: Protocol for a Feasibility Study to ...
WebOct 7, 2024 · Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders’ groundbreaking discoveries in RNA … WebOct 23, 2024 · mRNA-based therapeutics have emerged as a highly appealing new class of drugs, revolutionizing cancer immunotherapy by finding application in different types of anticancer approaches, such as therapeutic vaccines, monoclonal antibodies, immunomodulatory drugs and CAR cell therapies (Van Lint et al., 2012; Kranz et al., … Web2 days ago · The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The versatile delivery platform is also suited for mRNA and other types of RNA therapeutics and shall be leveraged via out-licensing to pharma or biotech … profitable herblore training osrs